"The AI Dog Vaccine" parties release complete technical plan: 300GB of genetic data, three chatbots with specific roles, from target selection to medication timing.

According to 1M AI News monitoring, Paul Conyngham, founder of an Australian AI consultancy company, posted a long-form article on X revealing for the first time the complete technical blueprint for designing a personalized mRNA cancer vaccine for his dog Rosie using an AI chatbot. Rosie is an 8-year-old Staffordshire Bull Terrier mixed-breed dog that was diagnosed with malignant mast cell cancer in May 2024, and the veterinarian determined she had only a few months to live.

Conyngham has no background in biology; the entire process relies on the coordinated division of labor among three AI chatbots: ChatGPT, Gemini, and Grok. He first completed Rosie’s whole-genome sequencing and RNA sequencing—about 300GB of raw data—through Professor Martin Smith at the Ramaciotti Centre of the University of New South Wales (UNSW) and the team at the Garvan Institute. He then used ChatGPT to design a bioinformatics analysis pipeline, employed AlphaFold 2 to model the structures of mutated proteins, and ultimately identified a c-KIT gene mutation through cross-validation between DNA and RNA data, selecting 7 neoantigen target sites. Gemini was responsible for building the multi-epitope vaccine sequence, while Grok completed the structural stability validation.

The vaccine was manufactured by Professor Pall Thordarson and his team at UNSW’s mRNA research institute, and was administered by Professor Rachel Allavena’s team at the University of Queensland School of Veterinary Science. The treatment plan was not just the vaccine; it was a triple therapy designed with AI assistance: the mRNA vaccine trains the immune system to recognize cancer cells, a tyrosine kinase inhibitor blocks cancer cell proliferation and angiogenesis driven by the c-KIT mutation, and a PD-1 checkpoint inhibitor removes the inhibitory signals that cancer cells send to T cells. The dosing schedule for the three components was planned with help from ChatGPT and Gemini, because immunosuppressive drugs and an immune-activating vaccine cannot be used at the same time.

Treatment began in December 2025. Three months later, two tumors on Rosie’s legs shrank significantly, but one tumor on her hip did not respond. It was surgically removed and submitted for genomic analysis, which preliminarily showed that its mutation profile differed from the cancer targeted by the vaccine design. Conyngham concluded that the AI chatbots made it so that “one person has the capability of an entire research institute,” covering workflow planning, educational learning, technical troubleshooting, compliance paperwork, and scientific design. He said he is evaluating the possibility of scaling up this process, “it won’t stop at one dog.”

Experts note that this is only a single case and not a controlled study, and it does not constitute evidence that AI can cure cancer.